ReviewJournal of intensive medicine2026
N6-methyladenosine methylation in acute lung injury: Mechanisms and research progress.
Review in Journal of intensive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m6A) methylation is the most prevalent and abundant internal post-transcriptional RNA modification in eukaryotic cells, playing an important regulatory role in various biological processes. The biological functions of m6A modification are dynamically and reversibly mediated by methyltransferases (writers), demethylases (erasers), and m6A binding proteins (readers). Acute lung injury (ALI) is a common critical condition characterized by diffuse edema within the pulmonary interstitium and alveoli, and is associated with high morbidity and mortality. Recent studies have identified that aberrant expression of m6A regulators is closely associated with ALI development. This review highlights the progress in research on m6A writers, erasers, and readers in ALI, focusing on their molecular regulatory mechanisms. Elucidating the molecular mechanisms of m6A and its associated proteins in ALI may reveal new therapeutic strategies and targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.